



21 January 2022

FABERCO LIFE SCIENCES INC.

2nd and 3rd Floor, One Armstrong Building
Armstrong Avenue, Moonwalk Subdivision Phase 1
Parañaque City, Metro Manila 1709

Amendment to the Emergency Use Authorization (EUA) for Molnupiravir
[MOLNARZ]

This refers to the request to amend the Emergency Use Authorization (EUA) dated 22 December 2021 for the COVID-19 Drug Molnupiravir [MOLNARZ] (“COVID-19 Drug Molnupiravir”) to extend the product shelf-life.

After due consideration, the Food and Drug Administration (FDA) is updating the authorization for the COVID-19 Drug Molnupiravir to extend the shelf life to twelve (12) months.

The foregoing revisions are made pursuant to the discretionary power of the FDA under Section 6 of Executive Order (EO) No. 121, entitled *"Granting Authority to the Director General of the Food and Drug Administration to Issue Emergency Use Authorization for COVID-19 Drugs and Vaccines, Prescribing Conditions Therefor, and for Other Purposes,"* to revisit any issued EUA as may be appropriate to protect the general public health and safety.

The details of the COVID-19 Drug Molnupiravir are as follows:

| | |
|----------------------------------|---|
| Product Name: | Molnupiravir [MOLNARZ] |
| Dosage Strength and Form: | 200 mg capsule |
| Pharmacologic category: | Drug |
| Storage: | Store below 30°C |
| Shelf Life: | 12 months |
| Packaging: | HDPE container of 40's |
| Manufacturer: | Aurobindo Pharma Limited - Unit III Survey 313 and 314, Bachupally, Bachupally Mandal, Medchal-Malkajgiri District, Telangana State, India |
| Indication: | Indicated for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults 18 years old and above with a positive SARS-COV-2 |

diagnostic test and who are at risk for developing severe illness

After careful consideration of the application, with all its supporting documents and a review of local experts, the FDA has been satisfied that all the conditions for the issuance of an EUA exist as provided under Executive Order (EO) No. 121, s. 2020 entitled *“Granting Authority to the Director General of the Food and Drug Administration to Issue Emergency Use Authorization for COVID-19 Drugs and Vaccines, Prescribing Conditions Therefor, and for Other Purposes,”* particularly:

1. Based on the totality of evidence available to date, including data from adequate and well- known controlled trials, it is reasonable to believe that the drug or vaccine may be effective to prevent, diagnose, or treat COVID-19;
2. The known and potential benefits of the drug or vaccine, when used to diagnose, prevent, or treat COVID-19, outweigh the known and potential risks of the drug or vaccine as of date; and
3. There is currently no adequate, approved and available alternative to the product for diagnosing, preventing or treating COVID-19.

In issuing this EUA, reliance has been accorded to the emergency use authorization given by the mature and established National Regulatory Authority (NRA) of the United Kingdom. Under Section 5 of EO No. 121, the Director General of the FDA has been granted power to implement recognition processes of established regulatory authorities.

This EUA is not a marketing authorization or a Certificate of Product Registration (CPR). Hence, this EUA cannot be used as an authorization to market the drug commercially.

While the evaluation process was facilitated, strict conditions on the authorization granted in this Letter shall be imposed as follows:

I. Scope

The scope of the EUA shall be limited as follows:

- A. Faberco Life Sciences Inc. shall supply the COVID-19 Drug Molnupiravir only to the Department of Health (DOH) or the National Task Force Against COVID-19 (NTF) consistent with the terms and conditions of this EUA.

The DOH or the NTF is authorized to procure or purchase COVID-19 Drug Molnupiravir in line with the COVID-19 management and prevention program.

- B. The COVID-19 Drug Molnupiravir shall be delivered to healthcare facilities and administered only by healthcare providers, and used only for COVID-19 according to the approved indication stated herein.

Healthcare facility, and healthcare provider, including physicians and nurses, as used in this EUA refer to those designated by the DOH or the NTF to receive and administer the COVID-19 Drug Molnupiravir, in accordance with the COVID-19 management and prevention program.

II. Posology and Method of Administration

COVID-19 Drug Molnupiravir should be supplied as a white to off white granular powder filled in hard capsules. COVID-19 Drug Molnupiravir 800mg (four 200mg capsules) should be administered orally every 12 hours for five (5) days. This should be given as soon as possible after a diagnosis of COVID-19 has been made and within 5 days of symptom onset.

COVID-19 Drug Molnupiravir is not recommended for women with childbearing potential, pregnant and lactating women.

III. Storage and Supply Chain Management

In the absence of agreement with the DOH or NTF, Faberco Life Sciences Inc. shall ensure that appropriate storage, transport, distribution, handling and supply chain is maintained until the product is delivered to healthcare facilities and administered by healthcare providers consistent with the terms of this letter, and ensure that a contingency plan is in place.

IV. Pharmacovigilance

Faberco Life Sciences Inc. shall have a comprehensive pharmacovigilance system for the COVID-19 Drug Molnupiravir following system or protocol for a registered drug and biologic product as stated in the FDA Circular No. 2020-003. Submission of serious and non-serious adverse reaction reports is mandatory.

Faberco Life Sciences Inc. shall ensure compliance with the Risk Management Plan (RMP) along with the Philippine-specific Annex. Additional pharmacovigilance activities such as interventional and non-interventional studies (ongoing or new studies, or additional activities) shall be implemented as stated in the RMP. The RMP must be updated whenever there is a significant change which may affect the benefit-risk profile of the drug or when an important milestone is reached.

Faberco Life Sciences Inc. shall submit monthly summary safety reports as planned and discussed in the RMP.

V. Responsibility of Healthcare Facilities and Healthcare Providers

Under FDA Circular No. 2020-036 or the *Guidelines for the Issuance of Emergency Use Authorization for Drugs and Vaccines for COVID-19*, the pharmacovigilance obligations and post-authorization commitments imposed in the Letter shall be shared to the fullest extent possible and applicable by the national procurer and health program implementors. Healthcare facilities and healthcare providers shall have the following responsibilities.

A. Healthcare facilities shall:

1. Receive the COVID-19 Drug Molnupiravir in sites identified by DOH, and ensure appropriate storage and supply chain management is maintained in

said facilities, in the absence of an agreement with Faberco Life Sciences Inc.;

2. Ensure administration of the COVID-19 Drug Molnupiravir is consistent with the terms of this Letter, latest product information and the COVID-19 management and treatment program; and
3. Ensure that healthcare providers of the COVID-19 Drug Molnupiravir are aware of this Letter of Authorization and the terms herein and any subsequent amendments thereof, instructed about the means which they are to obtain and administer the COVID-19 Drug Molnupiravir, and provided with approved fact sheets.

B. On the other hand, healthcare providers shall:

1. Administer the COVID-19 Drug Molnupiravir, in accordance with this EUA, and participate and comply with the terms and training required by the DOH for the COVID-19 management and treatment program;
2. Provide fact sheets to the recipients and caregivers, and provide necessary information for receiving their doses;
3. Obtain written informed consent from the recipient of the COVID-19 Drug Molnupiravir prior to administration;
4. Report any Adverse Drug Reaction (ADR) on the use of the COVID-19 Drug Molnupiravir;
5. Monitor and comply with drug management requirements (e.g. obtaining, tracking and handling drug) of the DOH; and
6. Ensure that records associated with this EUA are maintained until notified by FDA. Such records shall be made available to DOH and FDA for inspection upon request.

Notwithstanding the foregoing, Faberco Life Sciences Inc. has the ultimate responsibility for monitoring the safety and quality of the COVID-19 Drug Molnupiravir.

VI. Validity

Unless otherwise revoked, this EUA shall be valid only within the duration of the declared public health emergency due to COVID-19, or upon issuance of a marketing authorization/Certificate of Product Registration.

In the event that the declared public health emergency is lifted, or when a COVID-19 drug or vaccine is registered with the FDA, this EUA shall have a provisional validity for a period of one (1) year from date of lifting of the declaration or registration of the drug or vaccine for the sole purpose of exhausting remaining products.

This EUA is subject to revocation, suspension or cancellation due to violations of pharmacovigilance obligations and post authorization commitments, as well as any violation of the EO No. 121, and RA 3720 as amended by RA No. 9711, FDA Circular No. 2020-036, and other rules and regulations issued thereunder.

For strict compliance.